* Twist Bioscience Corp is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2024
* The South San Francisco California-based company is expected to report a 17.4% increase in revenue to $70.655 million from $60.18 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.The company's guidance on February 2 2024, for the period ended March 31, was for revenue between $70.00 million and $71.00 million.
* LSEG's mean analyst estimate for Twist Bioscience Corp is for a loss of 78 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Twist Bioscience Corp is $41.50, above its last closing price of $32.03.
The company's guidance on February 2 2024 for the period ended March 31 was for gross profit margin of USD39%. Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.78 -0.78 -0.75 Beat 3.5
Jun. 30 2023 -0.88 -0.92 -0.81 Beat 12.1
Jun. 30 2023 -1.13 -1.14 -0.78 Beat 31.5
Mar. 31 2023 -1.10 -1.12 -1.04 Beat 7.2
Dec. -1.12 -1.13 -0.74 Beat 34.7
31 2022
Sep. 30 2022 -1.25 -1.25 -0.91 Beat 27.1
Jun. 30 2022 -1.31 -1.31 -1.08 Beat 17.5
Mar. 31 2022 -1.28 -1.28 -1.13 Beat 11.5
This summary was machine generated April 30 at 22:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments